30th Jun 2025 11:03
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.
----------
AIM - WINNERS
----------
MediaZest PLC, up 26% at 0.079 pence, 12-month range 0.050p-0.10p. The Woking, England-based audio-visual technology company swings to pretax profit of GBP56,000 in the six months that ended March 31, from a GBP141,000 loss the year before. This is driven by revenue rising 58% to GBP1.9 million from GBP1.2 million. Cost of sales increases 65% to GBP779,000 from GBP472,000 and administrative expenses are up 25% to GBP1.0 million from GBP803,000. "We are delighted with the progress seen in H1 FY25 and expect continued momentum through the remainder of the financial year and into FY26 and FY27," says Chief Executive Officer Geoff Robertson. "The group continues to win new projects both with existing and new clients, driving recurring revenue streams and delivering organic growth. With our subsidiary in Europe going from strength to strength we are very optimistic about the future and prospects for significant further growth."
----------
AIM - LOSERS
----------
CRISM Therapeutics Corp, down 37% at 13.20p, 12-month range 5.00p-30.90p. The British Virgin Islands-based pharmaceutical firm raises GBP800,000 before expenses through a placing of 6.7 million new shares at 12 pence each. Each placing share has an attaching grant of warrants on a one for two basis, exercisable at 24p per share and expiring 24 months after the admission of the placing shares to AIM. CRISM also announces a retail offer to raise up to GBP100,000, at an issue price of 12p per share. Proceeds from both rounds of fundraising will be used to progress the development of its lead product, ChemoSeed. "The strong support from investors in this fundraising reflects the positive progress we have delivered since joining AIM last year," says Chief Executive Officer Andrew Webb. "We are now at a very exciting stage in the development of the company as we move closer to the start of our phase 2 trial in glioblastoma using our novel drug delivery platform, ChemoSeed...With this funding we now have the opportunity to accelerate the approval and commercialisation of a new, much needed treatment for this devastating disease."
----------
Touchstone Exploration Inc, down 20% at 16.08p, 12-month range 14.50p-39.00p. The onshore oil and gas producer in Trinidad says GBP10.3 million out of the GBP15.4 million gross proceeds from the private placement arranged by Portillion Capital Asset Management and Oak Securities has still not been received despite "repeated assurances" from Portillion and Oak Securities. This includes GBP10 million relating to Portillion's subscription commitment. The extended deadline to complete the placement under the conditional approval granted by the Toronto Stock Exchange expired on Friday, meaning Touchstone raised GBP5.1 million in total proceeds. "The company is reviewing its options in respect of Portillion's failure to fulfil its subscription commitment under the placement," says Touchstone. The firm "remains focused on securing the funding necessary to continue its 2025 capital program, including meeting its obligations under the fourth amended and restated loan agreement with Republic Bank". Under the terms of the loan agreement, Touchstone must raise at least around USD18 million before the end of 2025.
----------
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
MediazestCrism TheraCeladon Pharmaceuticals